On Monday 22 July, the European Commission announced that it had accepted commitments offered by the pharmaceutical company Vifor to address possible anti-competitive behaviour.
The Commission opened an investigation on 20 June 2022, fearing that Vifor had abused its dominant position for several years in several national markets for the supply of intravenous iron-based medicines (see EUROPE B12975A18) by conducting a misleading communication campaign, which may have hampered the...